|
CN1898221A
(zh)
|
2003-09-06 |
2007-01-17 |
沃泰克斯药物股份有限公司 |
Atp－结合弹夹转运蛋白的调控剂
|
|
US7407976B2
(en)
*
|
2003-11-14 |
2008-08-05 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and oxazoles useful as modulators of ATP-Binding Cassette transporters
|
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
HUE032540T2
(en)
|
2004-06-24 |
2017-09-28 |
Vertex Pharma |
Modulators of ATP-binding cassette transporters
|
|
ATE512145T1
(de)
|
2005-08-11 |
2011-06-15 |
Vertex Pharma |
Modulatoren des cystic fibrosis transmembrane conductance regulators
|
|
EP2395002B1
(en)
|
2005-11-08 |
2014-06-18 |
Vertex Pharmaceuticals Inc. |
Pharmaceutical composition containing a heterocyclic modulator of atp-binding cassette transporters.
|
|
CN101395147B
(zh)
|
2005-12-28 |
2013-05-29 |
弗特克斯药品有限公司 |
作为atp-结合盒转运蛋白调节剂用于治疗囊性纤维化的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物及相关化合物
|
|
CA2635581C
(en)
|
2005-12-28 |
2017-02-28 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
US7671221B2
(en)
*
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
PT2674428T
(pt)
|
2006-04-07 |
2016-07-14 |
Vertex Pharma |
Modeladores de transportadores de cassetes de ligação de atp
|
|
USRE50453E1
(en)
|
2006-04-07 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
|
NZ581259A
(en)
|
2007-05-09 |
2012-07-27 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
HUE028426T2
(en)
|
2007-08-24 |
2016-12-28 |
Vertex Pharma |
Isothiazolopyridinones for (inter alia) treating cystic fibrosis
|
|
AU2008310734B2
(en)
|
2007-10-10 |
2014-06-05 |
Parion Sciences, Inc. |
Delivering osmolytes by nasal cannula
|
|
ES2556080T3
(es)
*
|
2007-11-16 |
2016-01-12 |
Vertex Pharmaceuticals Incorporated |
Moduladores de isoquinolina de transportadores de casete de unión a ATP
|
|
UA95199C2
(en)
*
|
2007-12-07 |
2011-07-11 |
Вертекс Фармасьютикалз Инкорпорейтед |
Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
LT2639223T
(lt)
|
2007-12-07 |
2017-06-26 |
Vertex Pharmaceuticals Incorporated |
Cikloalkilkarboksiamido-piridino benzenkarboksirūgščių gamybos būdas
|
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
|
UA102534C2
(xx)
|
2007-12-07 |
2013-07-25 |
Вертекс Фармасьютикалз Инкорпорейтед |
ТВЕРДА ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДІОКСОЛ-5-ІЛ)-ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ (ВАРІАНТИ)$ТВЕРДАЯ ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДИОКСОЛ-5-ИЛ)-ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ (ВАРИАНТЫ)
|
|
NZ602030A
(en)
|
2008-02-28 |
2014-02-28 |
Vertex Pharma |
Heteroaryl derivatives as cftr modulators
|
|
NZ616097A
(en)
|
2008-03-31 |
2015-04-24 |
Vertex Pharma |
Pyridyl derivatives as cftr modulators
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
MX2011003249A
(es)
*
|
2008-09-29 |
2011-05-19 |
Vertex Pharma |
Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
|
|
AR074060A1
(es)
|
2008-10-23 |
2010-12-22 |
Vertex Pharma |
Moduladores del regulador de conductancia transmembrana de la fibrosis quistica
|
|
US8367660B2
(en)
|
2008-12-30 |
2013-02-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
EP2821400B1
(en)
|
2009-03-20 |
2017-09-27 |
Vertex Pharmaceuticals Incorporated |
Process for making modulators of cystic fibrosis transmembrane conductance regulator
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
NZ602795A
(en)
|
2010-04-07 |
2015-01-30 |
Vertex Pharma |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
CN102917692A
(zh)
|
2010-04-07 |
2013-02-06 |
弗特克斯药品有限公司 |
3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法
|
|
CA2797118C
(en)
|
2010-04-22 |
2021-03-30 |
Vertex Pharmaceuticals Incorporated |
Process of producing cycloalkylcarboxamido-indole compounds
|
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
|
CN102675280B
(zh)
*
|
2011-03-09 |
2015-01-14 |
中国科学院上海有机化学研究所 |
含三氟甲基的吲哚酮类化合物及其制备方法和应用
|
|
JP6110319B2
(ja)
*
|
2011-03-14 |
2017-04-05 |
スリーエム イノベイティブ プロパティズ カンパニー |
ナノ構造化物品
|
|
CN103732213A
(zh)
|
2011-06-07 |
2014-04-16 |
帕里昂科学公司 |
治疗方法
|
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
|
AR086745A1
(es)
|
2011-06-27 |
2014-01-22 |
Parion Sciences Inc |
3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
|
|
AU2012335714B2
(en)
|
2011-11-08 |
2017-04-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
RU2692779C2
(ru)
|
2012-02-27 |
2019-06-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Фармацевтическая композиция и ее введения
|
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
EP3366680B1
(en)
|
2012-05-29 |
2020-05-13 |
Parion Sciences, Inc. |
Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
|
|
AU2013290444B2
(en)
|
2012-07-16 |
2018-04-26 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
|
ES2674665T3
(es)
|
2012-12-17 |
2018-07-03 |
Parion Sciences, Inc. |
Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
|
|
CN104995178B
(zh)
|
2012-12-17 |
2018-06-26 |
帕里昂科学公司 |
3，5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
|
|
RU2015129065A
(ru)
|
2012-12-17 |
2017-01-25 |
Пэрион Сайенсиз, Инк. |
Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов
|
|
BR112016010403A2
(pt)
|
2013-11-12 |
2017-08-08 |
Vertex Pharma |
Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr
|
|
CA2944140C
(en)
|
2014-04-15 |
2022-10-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
|
|
JP2016017049A
(ja)
*
|
2014-07-08 |
2016-02-01 |
国立研究開発法人国立長寿医療研究センター |
新規ベンズオキサジン誘導体及びこれを含有する医薬
|
|
AU2015328174B2
(en)
|
2014-10-06 |
2020-05-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
RU2749213C2
(ru)
|
2014-10-07 |
2021-06-07 |
Вертекс Фармасьютикалз Инкорпорейтед |
Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
|
|
BR112017009194A2
(pt)
|
2014-10-31 |
2017-12-26 |
Abbvie Sarl |
tetra-hidropiranos substituídos e método de uso
|
|
US10302602B2
(en)
|
2014-11-18 |
2019-05-28 |
Vertex Pharmaceuticals Incorporated |
Process of conducting high throughput testing high performance liquid chromatography
|
|
WO2016193812A1
(en)
|
2015-06-02 |
2016-12-08 |
Abbvie S.A.R.L. |
Substituted pyridines and method of use
|
|
US9840513B2
(en)
|
2015-07-16 |
2017-12-12 |
Abbvie S.Á.R.L. |
Substituted tricyclics and method of use
|
|
TWI720032B
(zh)
|
2015-10-09 |
2021-03-01 |
比利時商葛萊伯格有限公司 |
Ｎ－磺醯化吡唑并﹝３，４－ｂ﹞吡啶－６－甲醯胺及其使用方法
|
|
MX2018004364A
(es)
|
2015-10-09 |
2018-08-16 |
Abbvie Sarl |
Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
|
|
CA3016303A1
(en)
|
2016-04-26 |
2017-11-02 |
Abbvie S.A.R.L. |
Modulators of cystic fibrosis transmembrane conductance regulator protein
|
|
WO2017197101A1
(en)
|
2016-05-12 |
2017-11-16 |
Research Triangle Institute |
Vinylogous phenethylamines as neurotransmitter releasers
|
|
US10138227B2
(en)
|
2016-06-03 |
2018-11-27 |
Abbvie S.Á.R.L. |
Heteroaryl substituted pyridines and methods of use
|
|
US9981910B2
(en)
*
|
2016-10-07 |
2018-05-29 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
US10399940B2
(en)
|
2016-10-07 |
2019-09-03 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
JOP20190125B1
(ar)
|
2016-12-09 |
2022-03-14 |
Vertex Pharma |
مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
|
|
US20200123137A1
(en)
|
2016-12-20 |
2020-04-23 |
AbbVie S.à.r.l. |
Deuterated cftr modulators and methods of use
|
|
TW201831471A
(zh)
|
2017-02-24 |
2018-09-01 |
盧森堡商艾伯維公司 |
囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
|
|
EP3634402A1
(en)
|
2017-06-08 |
2020-04-15 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
|
AU2018304168B2
(en)
|
2017-07-17 |
2023-05-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
|
US10988454B2
(en)
|
2017-09-14 |
2021-04-27 |
Abbvie Overseas S.À.R.L. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
CA3085006A1
(en)
|
2017-12-08 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2019193062A1
(en)
|
2018-04-03 |
2019-10-10 |
Abbvie S.Á.R.L |
Substituted pyrrolidines and their use
|
|
WO2020048826A1
(en)
|
2018-09-03 |
2020-03-12 |
Bayer Aktiengesellschaft |
5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
|
|
US11345691B2
(en)
|
2019-06-03 |
2022-05-31 |
AbbVie Global Enterprises Ltd. |
Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
US11236067B2
(en)
|
2019-07-12 |
2022-02-01 |
Orphomed, Inc. |
Compound for treating cystic fibrosis
|
|
CN114981243A
(zh)
|
2019-11-12 |
2022-08-30 |
健赞公司 |
用于治疗由cftr活性缺陷介导的疾病和病状的6元杂芳基氨基磺酰胺
|
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
US12324802B2
(en)
|
2020-11-18 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
US20220211692A1
(en)
|
2021-01-06 |
2022-07-07 |
AbbVie Global Enterprises Ltd. |
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
|
|
WO2022150173A1
(en)
|
2021-01-06 |
2022-07-14 |
AbbVie Global Enterprises Ltd. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
WO2023034992A1
(en)
|
2021-09-03 |
2023-03-09 |
Genzyme Corporation |
Indole compounds and methods of use
|
|
WO2023034946A1
(en)
|
2021-09-03 |
2023-03-09 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
|
WO2024054845A1
(en)
|
2022-09-07 |
2024-03-14 |
Sionna Therapeutics |
Macrocycic compounds, compositions, and methods of using thereof
|
|
WO2024054851A1
(en)
|
2022-09-07 |
2024-03-14 |
Sionna Therapeutics |
Macrocyclic compounds, compositions and methods of using thereof
|
|
EP4583972A1
(en)
|
2022-09-07 |
2025-07-16 |
Sionna Therapeutics Inc. |
Macrocyclic compounds, compositions, and methods of using thereof
|
|
WO2025132358A1
(en)
|
2023-12-21 |
2025-06-26 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases
|